poornima lagadapati
Active member
Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and they will be discharged soon.
MOSCOW: Russia has become the first nation to complete clinical trials of Covid-19 vaccine on humans, and the results have proven the medication's effectiveness, the media reported on Sunday.
Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and they will be discharged soon.
"The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20," Smolyarchuk was quoted as saying in the report.
There was, however, no further information on when this vaccine would enter commercial production stage.
Russia had allowed clinical trials of two forms of a potential Covid-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.
The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.
Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.
The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.
After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.
Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.
MOSCOW: Russia has become the first nation to complete clinical trials of Covid-19 vaccine on humans, and the results have proven the medication's effectiveness, the media reported on Sunday.
Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and they will be discharged soon.
"The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20," Smolyarchuk was quoted as saying in the report.
There was, however, no further information on when this vaccine would enter commercial production stage.
Russia had allowed clinical trials of two forms of a potential Covid-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.
The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.
Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.
The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.
After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.
Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.